Last $6.92 USD
Change Today +0.25 / 3.75%
Volume 542.7K
OSUR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (OSUR) Snapshot

Open
$6.61
Previous Close
$6.67
Day High
$6.94
Day Low
$6.58
52 Week High
03/6/14 - $8.60
52 Week Low
06/28/13 - $3.75
Market Cap
391.7M
Average Volume 10 Days
561.3K
EPS TTM
$-0.30
Shares Outstanding
56.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORASURE TECHNOLOGIES INC (OSUR)

orasure technologies inc (OSUR) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (OSUR) Details

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies. It also offers other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The company’s principal products comprise OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene DISCOVER, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT L2P, Intercept, MICRO-PLATE DOA Assays, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, it manufactures and sell oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, the company offers medical devices used for the removal of benign skin lesions by cryosurgery or freezing; certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and the FDA 510(k) cleared Q.E.D. rapid point-of-care saliva alcohol test. OraSure Technologies, Inc. sells its products to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities in the United States and internationally. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.

293 Employees
Last Reported Date: 03/14/14
Founded in 1979

orasure technologies inc (OSUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $563.4K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $442.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $319.7K
Executive Vice President of Marketing and Sal...
Total Annual Compensation: $362.0K
Compensation as of Fiscal Year 2013.

orasure technologies inc (OSUR) Key Developments

OraSure Technologies, Inc. Presents at Raymond James 35th Annual Institutional Investors Conference, Mar-03-2014 08:40 AM

OraSure Technologies, Inc. Presents at Raymond James 35th Annual Institutional Investors Conference, Mar-03-2014 08:40 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States. Speakers: Douglas A. Michels, Chief Executive Officer, President and Director.

Orasure Technologies Incorporated Announces Executive Changes

OraSure Technologies Incorporated announced that Dr. Steven Lee, its Executive Vice President Research and Development and Chief Science Officer has announced that he will be retiring from OraSure effective at the end of February. The company also announced the promotion of Dr. Eric Whitters from Director of Research and Development to Senior Vice President of Research and Development, Regulatory, Quality and Clinical Affairs effective March 01, 2014. Eric will take over Steve’s responsibilities. He will be a member of its internal executive committee and he will report directly to me. Eric joined OraSure in November of 2012 and has over 20 years of experience in the diagnostic industry. Before coming to OraSure, Eric served as Vice President of Research and Development at Novartis Diagnostics and as a Director of Technical Operations at Siemens Healthcare Diagnostics.

OraSure Technologies, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for the First Quarter of 2014

OraSure Technologies Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company's net revenues were $28.768 million compared with $22.144 million a year ago. Operating income was $6.063 million compared with operating loss of $6.15 million a year ago. Income before income taxes was $6.227 million compared with loss before income taxes of $6.125 million a year ago. Net income was $6.213 million or $0.11 per basic and diluted share compared with net loss of $5.866 million or $0.12 per basic and diluted share a year ago. Cash generated by operations in the fourth quarter of 2013 was $11.4 million. For the year, the company's net revenues were $98.94 million compared with $87.82 million a year ago. Operating loss was $12.162 million compared with $16.27 million a year ago. Loss before income taxes was $11.962 million compared with $16.512 million a year ago. Net loss was $11.19 million or $0.20 per basic and diluted share compared with $15.115 million or $0.29 per basic and diluted share a year ago. Cash provided by operating activities was $8.286 million compared with cash used in operating activities of $5.373 million a year ago. Capital expenditures were $2.462 million compared with $2.019 million a year ago. During the fourth quarter and full-year period, net product revenues increased 31% and 15%, respectively, compared to the year ago periods. These increases were primarily due to sales of the Company's OraQuick In-Home HIV test and higher revenues from the Company's molecular collection systems subsidiary, DNA Genotek. The Company expects consolidated net revenues to range from $23.0 to $23.5 million and is projecting a consolidated net loss of approximately $0.13-$0.14 per share for the first quarter of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSUR:US $6.92 USD +0.25

OSUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akers Biosciences Inc $4.25 USD +0.41
Chembio Diagnostics Inc $3.10 USD -0.022
Momenta Pharmaceuticals Inc $11.10 USD -0.46
Nymox Pharmaceutical Corp $5.04 USD -0.2199
Sciclone Pharmaceuticals Inc $4.54 USD +0.07
View Industry Companies
 

Industry Analysis

OSUR

Industry Average

Valuation OSUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit www.orasure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.